Estrogens — natural and semisynthetic
ATC code: G03CA03 (Estradiol)
Brand names
Estrace, Climara, Vivelle-Dot, Divigel
Bio-identical 17β-estradiol — the principal endogenous estrogen of reproductive age. Binds estrogen receptors ERα and ERβ in reproductive tissues, bone, CNS, and cardiovascular system. Reduces vasomotor menopausal symptoms, prevents bone mineral density loss, and supports genitourinary epithelium. Oral tablets, transdermal patches, and gels exist — the transdermal route is preferred in patients with thrombosis risk, migraine, or hepatic disease.
First line
First-line for moderate-to-severe vasomotor menopausal symptoms (hot flashes, night sweats, sleep disturbance) in women under 60 or within 10 years of menopause per NAMS 2022, IMS 2016, BMS 2024. In women with an intact uterus, combine with a progestogen (micronized progesterone or dydrogesterone) is mandatory. In hysterectomized women, estradiol monotherapy. Transdermal preferred over oral in patients with VTE risk, migraine with aura, or hepatic disease.
Individual decision
In postmenopausal women with osteoporosis or high fracture risk, MHT reduces vertebral and non-vertebral fractures by 30–40 %. Primary prevention is justified only with concurrent vasomotor symptoms or in women under 60 with contraindications to bisphosphonates or denosumab. Endocrine Society 2019 and 2022 do not recommend MHT solely to prevent chronic disease in asymptomatic women.
Not recommended
— Anti-aging and longevity: Systemic estradiol (patches, gels, tablets) is marketed as an anti-aging and longevity tool – not for vasomotor symptoms or osteoporosis prevention, but for cosmetic skin rejuvenation, vascular protection and cognitive support in women without menopausal complaints. NAMS 2022, IMS 2024, and /ESCAP 2023 menopause guidelines do not support this use – MHT is indicated for moderate-to-severe vasomotor symptoms and/or premature estrogen deficiency, not as geroprotection. Long-term data on estrogen monotherapy in women without an objective MHT indication do not show benefit for longevity.
Not recommended
Per 2022, /, and NAMS 2022, MHT is not recommended for cardiovascular disease or dementia prevention in asymptomatic postmenopausal women. The WHI 2002 trial showed increased ischemic stroke and venous thromboembolism with oral forms. Modern data with transdermal forms are more favorable, but routine use for primary CVD prevention is not justified.
Contraindicated in pregnancy. Reliable contraception is required in reproductive-age patients on MHT.
Contraindicated during breastfeeding — suppresses lactation and transfers into milk.
estradiol is evaluated for the following indications with varying evidence strength: Menopausal symptoms (evidence tier A), Postmenopausal osteoporosis (evidence tier B), Primary cardiovascular prevention in individuals without established CVD (evidence tier F). See the full indication matrix with dosing and citations above on this page.
Common side effects of estradiol (≥ 1 in 100): Breast tenderness, Nausea, Headache, Breakthrough bleeding (especially first months), Mood swings, Bloating. See the Safety section for uncommon and serious reactions.
Contraindicated in pregnancy. Reliable contraception is required in reproductive-age patients on MHT.
Contraindicated during breastfeeding — suppresses lactation and transfers into milk.
estradiol is contraindicated in: Suspected or confirmed breast cancer; Suspected or confirmed hormone-dependent cancer (including endometrial); Undiagnosed vaginal bleeding; Active or recent venous thromboembolism; Active thrombotic disorders (arterial). Full list in the Safety section.